Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Does belatacept provide equivalent suppression of acute renal transplant rejection to ciclosporin?

Nature Clinical Practice Nephrology volume 2, pages 134–135 (2006)Cite this article

boxed-textVincenti F et al. (2005) Costimulation blockade with belatacept in renal transplantation. New Engl J Med 353: 770–781

This study underlines the potential benefits of using targeted biologic agents that avoid the generalized nonspecific toxic effects of conventional immunosuppressants in renal transplant recipients

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Sayegh MH and Turka LA (1998) The role of T-cell costimulatory activation pathways in transplant rejection N Engl J Med 338: 1813–1821

    Article  CAS  Google Scholar 

  2. Larsen CP et al. (2005) Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 5: 443–453

    Article  CAS  Google Scholar 

  3. Tran HT et al. (2000) Avoidance of cyclosporine in renal transplantation: effects of daclizumab, mycophenolate mofetil, and steroids. J Am Soc Nephrol 11: 1903–1909

    CAS  PubMed  Google Scholar 

  4. Kreis H et al. (2004) Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 15: 809–817

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Chloe Harman, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. the Warren E Grupe and John P Merrill Chair in Transplantation Medicine and Professor of Medicine and Pediatrics at Harvard Medical School and Director of the Transplantation Research Center in the Renal Division at the Brigham and Women's Hospital and Children's Hospital, Boston, MA, USA

    Mohamed H Sayegh

  2. the Director of the Renal Transplant Clinics at the Brigham and Women's Hospital, Assistant Professor of Medicine at Harvard Medical School and a Principal Investigator at the Transplantation Research Center at the Brigham and Women's Hospital and the Children's Hospital, Boston, MA, USA

    Anil Chandraker

Authors
  1. Mohamed H Sayegh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anil Chandraker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anil Chandraker.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sayegh, M., Chandraker, A. Does belatacept provide equivalent suppression of acute renal transplant rejection to ciclosporin?. Nat Rev Nephrol 2, 134–135 (2006). https://doi.org/10.1038/ncpneph0125

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpneph0125

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing